Photo of Alex Manini

Alex Manini

  • ASSOCIATE PROFESSOR Emergency Medicine
Print ProfilePrint Profile


  • B.S., Massachusetts Institute of Technology

  • Brigham & Women's Hospital / Massachusetts General Hospital Harvard Medical School
    Emergency Medicine

  • Brigham & Women's Hospital / Massachusetts General Hospital Harvard Medical School

  • M.S., New York University

  • Bellevue Hospital Center - NYU School of Medicine
    Medical Toxicology

  • MD, UCSF School of Medicine


    Dr. Manini is Associate Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai in New York City. He practices at Elmhurst Hospital Center with board certification in Emergency Medicine and Medical Toxicology. He received his undergraduate degree in biology from MIT, followed by an MD from UCSF and MS in clinical investigation at NYU. He trained in emergency medicine at the Harvard Affiliated Emergency Medicine Residency at Massachusetts General Hospital and Brigham and Women's Hospital in Boston, MA. He completed fellowship in medical toxicology at NYU/Bellevue in New York City.

    Dr. Manini has authored over 50 peer-reviewed publications and his current research interests include clinical studies to characterize and evaluate adverse cardiovascular events following acute drug overdose. In 2011 he was named the Young Investigator of the Year by the Society for Academic Emergency Medicine (SAEM) and in 2013 he was voted Young Investigator of the Year by the European Association of Poison Centres and Clinical Toxicologists (EAPCCT).  He has received research grant support from the National Institutes of Health, National Institute on Drug Abuse, National Center for Advancement of Translational Sciences, and the City of New York.


    Please click here to access Dr. Manini's biosketch:



  • 2013 -
    Young Investigator Award WINNER, XXXIII International Congress

  • 2013 -
    Fellow of the American College of Medical Toxicology

  • 2013 -
    Senior Reviewer
    Annals of Emergency Medicine

  • 2011 -
    Young Investigator of the Year
    Society of Academic Emergency Medicine (SAEM)

  • 2011 -
    The Dr. Harold and Golden Lamport Reseach Award
    Mount Sinai School of Medicine

  • 2006 -
    Department Award
    Emergency Medicine, MGH Clinical Research Day


Adverse Cardiovascular Events from Drug Overdose

Risk Factors
Serum Biomarkers
Genetic Polymorphism


Manini AF, Hoffman RS, McMartin K, Nelson LS. Relationship between serum glycolate and falsely elevated lactate in severe ethylene glycol poisoning. J Analytical Toxicol 2009; 33: 227-229.

Smith S, Manini AF, Szekely T, Hoffman RS. Bedside detection of urine Beta-hydroxybutyrate in diagnosing metabolic acidosis. Acad Emerg Med 2008; 15(8): 751-756.

Manini AF, Skolnick A, Nelson LS, Slater W, Hoffman RS. Electrocardiographic predictors of adverse cardiovascular events in suspected poisoning.. J Med Toxicol 2010; 6(2): 106-15.

Manini AF, Kumar A, Olsen D, Vlahov D, Hoffman RS. Utility of serum lactate to predict drug overdose fatality. Clin Toxicol ((Phila) 2010; 49(8): 730-6.

Manini AF, Nelson LS, Olsen D, Vlahov D, Hoffman RS. Medical examiner and medical toxicologist agreement on cause of death. Foresic Sci Int 2011; 206((1-3)): 71-6.

Leung L, Wilson D, Manini AF. Fatal Toxicity from symptomatic hyperlactatemia: Factors implicated with chronic NRTI use. Drug Saf 2011; 34(6): 521-7.

Manini AF, Nelson LS, Hoffman RS. Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. Am J Cardiovasc Drugs 2011; 11(3): 173-8.

Geib AJ, Liebelt E, Manini AF. Toxicology Investigators' Corsortium (ToxlC) . Clinical experience with intravenous lipid emulsion for drug-induced cardiovascular collapse. J Med Toxicol 2012; 8(1): 10-14.

Manini AF, Nelson LS, Stimmel B, Vlahov D, Hoffman RS. Incidence of adverse cardiovascular events in adults following drug overdose. Acad Emerg Med 2012; 19(7): 843-849.

Manini AF, Jacobs MM, Vlahov D, Hurd YL. Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population. J Med Toxicol 2013; 9(2): 148-54.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Manini did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


3 East 101st Street Floor 2 Room 207
New York, NY 10029